Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.11Last Year’s EPS
0.1Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -19.71%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
Certara's earnings call reflected a strong finish to 2024 with significant growth in software bookings and successful integration of strategic acquisitions. However, challenges such as cautious customer spending and elongated decision-making timelines dampened the overall outlook. The company's strategic investments in AI and software development are poised to drive future growth.Company Guidance
During the Certara Fourth Quarter 2024 Earnings Conference Call, the company provided guidance for 2025, projecting total revenue between $415 million and $425 million, which represents a growth of 8% to 10% over 2024. The company expects adjusted EBITDA margins to be in the range of 30% to 32%, with adjusted earnings per share anticipated to fall between $0.42 and $0.46. Certara's revenue growth is anticipated to be driven by continued software expansion, including contributions from the recent Chemaxon acquisition, expected to add between $23 million and $25 million in 2025. The company noted the challenging market environment, highlighting cautious spending behavior among customers and the impact of funding constraints, Medicare drug price negotiations, and geopolitical uncertainties. Despite these challenges, Certara is optimistic about its strategic investments in software development, particularly in integrating generative artificial intelligence and expanding its product offerings across the drug discovery and development phases.Strong Revenue Growth
Certara finished 2024 with revenue of $385.1 million, representing 9% reported growth versus 2023.
Software Bookings Growth
Fourth quarter software bookings reached $59.7 million, which increased 38% from the prior year period.
Successful Acquisitions
The integration of Chemaxon, Formedix, and Applied Biomass contributed positively, with Chemaxon generating $6.6 million revenue in Q4.
Expansion of Customer Base
Certara expanded its customer base to over 2,400 life sciences companies, with 431 customers having annual contract values exceeding $100,000.
Adjusted EBITDA Increase
Adjusted EBITDA in Q4 2024 was $33.5 million, up from $29.6 million in Q4 2023, maintaining a margin of 33%.
---
CERT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CERT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $12.33 | $12.40 | +0.57% |
| Nov 06, 2024 | $10.91 | $10.99 | +0.73% |
| Aug 06, 2024 | $15.08 | $13.03 | -13.59% |
| May 07, 2024 | $17.66 | $16.35 | -7.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Certara (CERT) report earnings?
Certara (CERT) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Certara (CERT) earnings time?
Certara (CERT) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CERT EPS forecast?
CERT EPS forecast for the fiscal quarter 2025 (Q1) is 0.11.
---